Heart Failure Clinical Trials

Find Heart Failure Clinical Trials Near You

Early Detection and IntervenTion in Heart Failure

Status: Recruiting
Location: See all (21) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice. The aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes: 1. increasing awareness of HF among patients and physicians, 2. using NT-proBNP testing for the early detection of HF in high-risk patients, and 3. promptly initiating guideline-directed HF treatment when the diagnosis is confirmed. The researchers will assess whether this strategy effectively reduces hospitalizations due to acute heart failure over an 18-month follow-up period.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• General consent (GC) has not been rejected.

• Age ≥ 65 years.

• Elective percutaneous coronary intervention\* (PCI), pulmonary vein isolation\* (PVI), pacemaker implantation\* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention\* (TAVI), major non-cardiac surgery\* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h).

⁃ Exclusion criteria are assessed on day 1 after the procedure

Locations
Other Locations
Austria
Universitätsklinik für Innere Medizin II
NOT_YET_RECRUITING
Vienna
Bulgaria
Queen Giovanna University Hospital
NOT_YET_RECRUITING
Sofia
Germany
University Hospital Freiburg-Bad Krozingen
NOT_YET_RECRUITING
Freiburg Im Breisgau
Universitätsklinikum der Ruhr-Universität Bochum
NOT_YET_RECRUITING
Herne
Herzzentrum Leipzig, Klinik für Innere Medizin/Kardiologie
NOT_YET_RECRUITING
Leipzig
Italy
University Hospital Pisa
NOT_YET_RECRUITING
Pisa
Netherlands
Erasmus MC Rotterdam
NOT_YET_RECRUITING
Rotterdam
Republic of Korea
Konkuk University Medical Center
RECRUITING
Seoul
Spain
University Hospital Ramón y Cajal Madrid
NOT_YET_RECRUITING
Madrid
Switzerland
KSA Kantonsspital Aarau
NOT_YET_RECRUITING
Aarau
Cantonal Hospital Baden
NOT_YET_RECRUITING
Baden
St. Claraspital AG
NOT_YET_RECRUITING
Basel
University Hospital Basel
RECRUITING
Basel
University Hospital Genève
NOT_YET_RECRUITING
Geneva
University Hospital Lausanne
NOT_YET_RECRUITING
Lausanne
Kantonsspital Luzern
NOT_YET_RECRUITING
Lucerne
Hospital Istituto Cardiocentro Ticino
NOT_YET_RECRUITING
Lugano
Kantonsspital St. Gallen
NOT_YET_RECRUITING
Sankt Gallen
Stadtspital Zürich
NOT_YET_RECRUITING
Zurich
University Hospital Zurich
NOT_YET_RECRUITING
Zurich
United Kingdom
Royal Infirmary Edinburgh
NOT_YET_RECRUITING
Edinburgh
Contact Information
Primary
Christian Müller, Prof. Dr.
Christian.Mueller@usb.ch
+41 61 328 65 49
Backup
Sonja Horvat, Dr.
sonja.horvat-csoti@usb.ch
Time Frame
Start Date: 2025-12-03
Estimated Completion Date: 2030-04
Participants
Target number of participants: 18000
Treatments
No_intervention: Phase I
Other: Phase II
Intervention
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Basel, Switzerland

This content was sourced from clinicaltrials.gov